课题基金 / 基金详情

项目摘要

项目成果

STUART L SCHREIBER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The phenotypic screens described in the accompanying Discovery Pipeline proposal do not directly identify the small-molecule target, yet target identification is vitally important to follow-up, medicinal chemistry efforts. Target identification, including both the therapeutic target and "off targets" that can result in unwanted "side effects", enables optimization of a compound's selectivity and reduction in the potential for side effects of a resultant drug. Target discovery and validation as it is currently practiced is a significant bottleneck to drug discovery. This proposal offers a solution to the target identification problem through the systematic use of three distinct and interdisciplinary approaches. Proteomic, genetic and computational methodologies have been developed at the Broad Institute and will be implemented as a critical follow-up to screening results. Specifically, we will: 1) develop a systematic, proteomic approach to identify targets that underlie smallmolecule screening discoveries; 2) combine small-molecule and RNAi methods to identify or to validate targets that underlie small-molecule screening discoveries; and 3) develop computational methods based on gene expression, small-molecule screening, and proteomic and RNAi data to identify pathways and targets that underlie small-molecule screening discoveries. The problem of target identification is one that may be solved not by a single 'killer' technology; rather, we envision the analytical integration of multiple, complementary approaches. Each of these is dependent upon a focused, interdisciplinary effort to a problem that is unlikely to be solvable with the expertise of one discipline alone. We are proposing to develop small-molecule drugs to alleviate unmet medical needs. In order to maximize a drug's potency and minimize a drug's unwanted side-effects, we need to understand all the proteins ("targets") that a drug candidate will interact with. This proposal seeks to use a combination of cutting-edge scientific approaches available at the Broad Institute to address the difficult problem of target identification.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.cell.2012.06.047
发表时间: 2012-08-31
期刊: Cell
影响因子: 64.5
作者: [Taipale M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD, Karras GI, Lindquist S]
通讯作者: Lindquist S
DOI: 10.1038/nbt.2620
发表时间: 2013-07
期刊: Nature biotechnology
影响因子: 46.9
作者: []
通讯作者:
DOI: 10.1177/1087057113520226
发表时间: 2014-06
期刊: Journal of biomolecular screening
影响因子: --
作者: [Dančík V, Carrel H, Bodycombe NE, Seiler KP, Fomina-Yadlin D, Kubicek ST, Hartwell K, Shamji AF, Wagner BK, Clemons PA]
通讯作者: Clemons PA
DOI: 10.1038/nchembio.1199
发表时间: 2013-04
期刊: Nature chemical biology
影响因子: 14.8
作者: [Schenone M, Dančík V, Wagner BK, Clemons PA]
通讯作者: Clemons PA
9
    Studies of Materials with Physiological Properties
    • 批准号:
      10187586
    • 项目类别:
    • 资助金额:
      $56.96万
    • 财政年份:
      2018
    • 负责人:
      STUART L SCHREIBER
    • 依托单位:
    Studies of Materials with Physiological Properties
    • 批准号:
      10424480
    • 项目类别:
    • 资助金额:
      $56.96万
    • 财政年份:
      2018
    • 负责人:
      STUART L SCHREIBER
    • 依托单位:
    Targeting vulnerabilities of therapy-resistant cancer cell states with small molecules
    • 批准号:
      10227768
    • 项目类别:
    • 资助金额:
      $119.61万
    • 财政年份:
      2017
    • 负责人:
      STUART L SCHREIBER
    • 依托单位:
    Targeting vulnerabilities of therapy-resistant cancer cell states with small molecules
    • 批准号:
      9362107
    • 项目类别:
    • 资助金额:
      $114.61万
    • 财政年份:
      2017
    • 负责人:
      STUART L SCHREIBER
    • 依托单位:
    海外基金